Acute regression of advanced and retardation of early aortic atheroma in immunocompetent apolipoprotein-E (apoE) deficient mice by administration of a second generation [E1-, E3-, polymerase-] adenovirus vector expressing human apoE

Human Molecular Genetics

Volumn 11, Issue 1, 2002, Pages 43-58

  Harris, Julian D ^a   Graham, Ian R ^a   Schepelmann, Silke ^b   Stannard, Anita K ^b   Roberts, Michael L ^a   Hodges, Bradley L ^c   Hill, Vannessa J ^a   Amalfitano, Andrea ^c   Hassall, David G ^d   Owen, James S ^b   Dickson, George ^a  

^a UNIVERSITY OF LONDON   (United Kingdom)

^b ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

^d GLAXOSMITHKLINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; APOLIPOPROTEIN E; CHOLESTEROL; LIPOPROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; AORTA ATHEROSCLEROSIS; ARTICLE; ATHEROGENESIS; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CYTOMEGALOVIRUS; DRUG BLOOD LEVEL; DYSLIPOPROTEINEMIA; FEMALE; GENE EXPRESSION; GENE TRANSFER; HUMORAL IMMUNITY; HYPERCHOLESTEROLEMIA; IMMUNOCOMPETENCE; LIVER; MOUSE; NONHUMAN; PRIORITY JOURNAL; TRANSGENE;

ADENOVIRIDAE; ANIMALIA; CYTOMEGALOVIRUS;

EID: 0036151865     PISSN: 09646906     EISSN: None     Source Type: Journal    
DOI: 10.1093/hmg/11.1.43     Document Type: Article

References (67)

1. Apolipoprotein E: Cholesterol transport protein with expanding role in cell biology
2. Molecular physiology of reverse cholesterol transport
3. A plasma lipoprotein containing only apolipoprotein E and with γ mobility on electrophoresis releases cholesterol from cells
4. Effects of the apolipoprotein E polymorphism on uptake and transfer of cell-derived cholesterol in plasma
5. Cholesterol efflux from macrophages and other cells
6. Apolipoprotein E allele-specific antioxidant activity and effects on cytotoxicity by oxidative insults and β-amyloid peptides
7. Antioxidants and coronary artery disease
8. Apolipoprotein E inhibits platelet aggregation through the L-arginine:nitric oxide pathway
9. Apolipoprotein E inhibition of proliferation of mitogen-activated T lymphocytes: Production of interleukin 2 with reduced biological activity
10. Genetic heterogeneity of apolipoprotein E and its influence on plasma lipid and lipoprotein levels
11. Spontaneous hypercholesterolemia and arterial lesions in mice lacking apolipoprotein E
12. ApoE-deficient mice develop lesions of all phases of atherosclerosis throughout the arterial tree
13. Treatment of severe hypercholesterolemia in apolipoprotein E-deficient mice by bone marrow transplantation
14. Prevention of atherosclerosis in apolipoprotein E-deficient mice by bone marrow transplantation
15. Retroviral gene therapy in apoE-deficient mice: ApoE expression in the artery wall reduces early foam cell lesion formation
16. Apolipoprotein E deficiency in mice: Gene replacement and prevention of atherosclerosis using adenovirus vectors
17. Phenotypic correction of hypercholesterolemia in apoE-deficient mice by adenovirus-mediated in vivo gene transfer
18. Liver-directed gene transfer and prolonged expression of three major human apoE isoforms in apoE-deficient mice
19. Rapid regression of atherosclerosis induced by liver-directed gene transfer of apoE in apoE-deficient mice
20. Complete atherosclerosis regression after human apoE gene transfer in apoE-deficient/nude mice
21. Intramuscular injection of a plasmid vector expressing human apolipoprotein E limits progression of xanthoma and aortic atheroma in apoE-deficient mice
22. Treatment of severe hypercholesterolemia in apolipoprotein E-deficient mice by intramuscular injection of plasmid DNA
23. Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy
24. Immune responses to viral antigens versus transgene product in the elimination of recombinant adenovirus-infected hepatocytes in vivo
25. Improved adenoviral vectors for gene therapy of Duchenne muscular dystrophy
26. Production and characterization of improved adenovirus vectors with the E1, E2b, and E3 genes deleted
27. -] adenovirus vector despite transduction of a neoantigen into immune-competent mice
28. Multiply deleted [E1, polymerase-, and pTP-] adenovirus vector persists despite deletion of the preterminal protein
29. Familial apolipoprotein E deficiency
30. Determination of the lower threshold of apolipoprotein E resulting in remnant lipoprotein clearance
31. Production of first generation adenovirus vectors: A review
32. Adenovirus-mediated transfer of low density lipoprotein receptor gene acutely accelerates cholesterol clearance in normal mice
33. In vivo hepatic gene therapy: Complete albeit transient correction of factor IX deficiency in hemophilia dogs
34. Adenovirus mediated expression of therapeutic plasma levels of human factor IX in mice
35. MHC class I-restricted cytotoxic lymphocytes to viral antigens destroy hepatocytes in mice infected with E1-deleted recombinant adenoviruses
36. Severe hypercholesterolemia and atherosclerosis in apolipoprotein E-deficient mice created by homologous recombination in ES cells
37. Expression of Coxsackie adenovirus receptor and αv-integrin does not correlate with adenovector targeting in vivo indicating anatomical vector barriers
38. Isolation of a common receptor for coxsackie B viruses and adenoviruses 2 and 5
39. Apolipoprotein E polymorphism and arteriosclerosis
40. Remnant lipoprotein metabolism: Key pathways involving cell-surface heparan sulfate proteoglycans and apolipoprotein E
41. Innate immune mechanisms dominate elimination of adenoviral vectors following in vivo administration
42. Prolongation of adenoviral transgene expression in mouse liver by T lymphocyte subset depletion
43. Hepatic gene therapy: Persistent expression of human α1-antitrypsin in mice after direct gene deliver in vivo
44. Evaluation of promoter strength for hepatic gene expression in vivo following adenovirus-mediated gene transfer
45. Reactivation of the previously silenced cytomegalovirus major immediate-early promoter in the mouse liver: Involvement of NFκB
46. Promoter attenuation in gene therapy: Interferon-γ and tumor necrosis-α transgene expression
47. Generation of mice carrying a mutant apolipoprotein E gene inactivated by gene targeting in embryonic stem cells
48. ApoE structure determines VLDL clearance and atherosclerosis risk in mice
49. 2-LpE, and α-LpE
50. Effect of macrophage-derived apolipoprotein E on established atherosclerosis in apolipoprotein E-deficient mice
51. Adenovirus-mediated gene transfer: Influence of transgene, mouse strain and type of immune response on persistence of transgene expression
52. Intravenous administration of an E1/E3-deleted adenoviral vector induces tolerance to factor IX in C57BL/6 mice
53. The molecular basis of a familial apoE deficiency. An acceptor splice site mutation in the third intron of the deficient apoE gene
54. Familial apolipoprotein (apo) E deficiency: Identification of a new kindred with a premature stop codon in the apoE gene
55. Transduction of dendritic cells by DNA viral vectors directs the immune response to transgene products in muscle fibers
56. Cellular and humoral immune responses to adenoviral vectors containing factor IX: Tolerization of factor IX and vector antigens allows for long-term expression
57. Novel vaccine approaches
58. Sustained correction of bleeding disorder in hemophilia B mice by gene therapy
59. Sustained expression of therapeutic level of factor IX in hemophilia B dogs by AAV-mediated gene therapy in liver
60. A simplified system for generating recombinant adenoviruses
61. Identification and DNA sequence of a human Apolipoprotein E cDNA clone
62. Isolation and characterization of packaging cell lines that coexpress the adenovirus E1, DNA polymerase, and the preterminal proteins: Implications for gene therapy
63. Methods for construction of adenovirus vectors
64. Characterization of the major apolipoproteins secreted by two human hepatoma cell lines
65. Serial passaging and differentiation of myogenic cells isolated from dystrophic mouse muscle
66. Gene correction of the apolipoprotein (apo) E2 phenotype to wild-type apoE3 by in situ chimeroplasty
67. Sustained expression of human apo A1 following adenoviral gene transfer in mice